Alnylam Pharmaceuticals
ALNY
#632
Rank
NZ$66.96 B
Marketcap
NZ$501.85
Share price
-4.32%
Change (1 day)
15.16%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): NZ$3.13

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$3.05. In 2023 the company made an earnings per share (EPS) of NZ-$5.98 an increase over its 2022 EPS that were of NZ-$15.74.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$3.13
2023NZ-$5.98-62%
2022NZ-$15.7429.03%
2021NZ-$12.20-3.36%
2020NZ-$12.63-8.48%
2019NZ-$13.807.67%
2018NZ-$12.8139.74%
2017NZ-$9.1712.94%
2016NZ-$8.1238.84%
2015NZ-$5.85-32.88%
2014NZ-$8.71259.44%
2013NZ-$2.42-31.25%
2012NZ-$3.53

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.20 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.50 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$73.08 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.64-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.24-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.41-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.10-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.59-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA